日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Advancing drug development in myelodysplastic syndromes

推进骨髓增生异常综合征的药物研发

Mina, Alain; McGraw, Kathy L; Cunningham, Lea; Kim, Nina; Jen, Emily Y; Calvo, Katherine R; Ehrlich, Lori A; Aplan, Peter D; Garcia-Manero, Guillermo; Foran, James M; Garcia, Jacqueline S; Zeidan, Amer M; DeZern, Amy E; Komrokji, Rami; Sekeres, Mikkael A; Scott, Bart; Buckstein, Rena; Tinsley-Vance, Sara; Verma, Amit; Wroblewski, Tanya; Pavletic, Steven; Norsworthy, Kelly

Considerations for Drug Development in Myelodysplastic Syndromes

骨髓增生异常综合征药物研发的考量因素

Sekeres, Mikkael A; Kim, Nina; DeZern, Amy E; Norsworthy, Kelly J; Garcia, Jacqueline S; de Claro, R Angelo; Theoret, Marc R; Jen, Emily Y; Ehrlich, Lori A; Zeidan, Amer M; Komrokji, Rami S

Minimal Residual Disease Data in Hematologic Malignancy Drug Applications and Labeling: An FDA Perspective

血液系统恶性肿瘤药物申请和标签中的微小残留病数据:FDA 的视角

Baines, Andrea C; Yazdy, Maryam Sarraf; Kasamon, Yvette L; Ershler, Rachel; Jen, Emily Y; Kanapuru, Bindu; Richardson, Nicholas C; Lane, Ashley; Carioti, Theresa; Theoret, Marc R; Pazdur, Richard; Gormley, Nicole J

FDA Approval Summary: Oral Azacitidine for Continued Treatment of Adults with Acute Myeloid Leukemia Unable to Complete Intensive Curative Therapy

FDA批准摘要:口服阿扎胞苷用于无法完成强化根治性治疗的急性髓系白血病成人患者的持续治疗

Jen, Emily Y; Wang, Xin; Li, Meng; Li, Hongshan; Lee, Shwu-Luan; Ni, Nina; Przepiorka, Donna; Vallejo, Jonathon; Leong, Ruby; Ma, Lian; Gehrke, Brenda J; McLamore, Sherita; Theoret, Marc R; de Claro, R Angelo

IL-2 regulates the expression of the tumor suppressor IL-24 in melanoma cells.

IL-2 调节黑色素瘤细胞中抑癌基因 IL-24 的表达

Jen Emily Y, Poindexter Nancy J, Farnsworth Elizabeth S, Grimm Elizabeth A